References
- Parums DV. Editorial: The 2021 European Society of Cardiology (ESC) guidelines on the real-world prevention of atherosclerotic cardiovascular disease (ASCVD). Med Sci Monit 2021;27:e9351721–3. doi: 10.12659/MSM.935172
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678
- Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 2016;389:695–712. doi: 10.1007/s00210-016-1252-4
- Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR agonists and metabolic syndrome: an established role? Int J Mol Sci 2018;19(4):1197. doi: 10.3390/ijms19041197
- Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009;29:706–11. doi: 10.1161/ATVBAHA.108.183160
- Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res 2016;103:236–52. doi: 10.1016/j.phrs.2015.12.001
- Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123–30. doi: 10.1016/j.amjcard.2012.12.037
- Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol 2015;8:189–99. doi: 10.1586/17512433.2015.1011125
- Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93. doi: 10.1161/01.cir.98.19.2088
- Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001;107:1423–32. doi: 10.1172/JCI10852
- Wójtowicz S, Strosznajder AK, Jeżyna M, Strosznajder JB. The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer’s disease and other neurodegenerative disorders. Neurochem Res 2020;45:972–88. doi: 10.1007/s11064-020-02993-5
- Hong K-S, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke 2015;17:282–301. doi: 10.5853/jos.2015.17.3.282
- Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213–21. doi: 10.1016/S0140-6736(13)62242-4
- Lee Y-C, Lin C-H, Wu R-M, Lin M-S, Lin J-W, Chang C-H, Lai M-S. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410–6. doi: 10.1212/WNL.0b013e31829d873c
- Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R. Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci 2014;6:71. doi: 10.3389/fnagi.2014.00071
- Losey P, Ladds E, Laprais M, Guevel B, Burns L, Bordet R, Anthony DC. The role of PPAR activation during the systemic response to brain injury. J Neuroinflammation 2015;12:99. doi: 10.1186/s12974-015-0295-7
- Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther 2008;326:966–74. doi: 10.1124/jpet.108.140368
- Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 2015;23:1144–70. doi: 10.1089/ars.2015.6317
- Aoyama K. Glutathione in the brain. Int J Mol Sci 2021;22(9):5010. doi: 10.3390/ijms22095010
- Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009;30:42–59. doi: 10.1016/j.mam.2008.05.005
- Macan M, Vukšić A, Žunec S, Konjevoda P, Lovrić J, Kelava M, Štambuk N, Vrkić N, Bradamante V. Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidaemic rats. Pharmacol Rep 2015;67:907–13. doi: 10.1016/j.pharep.2015.02.005
- Mohamadin AM, Elberry AA, Abdel Gawad HS, Morsy GM, Al-Abbasi FA. Protective effects of simvastatin, a lipid lowering agent, against oxidative damage in experimental diabetic rats. J Lipids 2011;2011:167958. doi: 10.1155/2011/167958
- Zeng H, Liu Z. Atorvastatin induces hepatotoxicity in diabetic rats via oxidative stress, inflammation, and anti-apoptotic pathway. Med Sci Monit 2019;25:6165–73. doi: 10.12659/MSM.915790
- Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 2002;53:463–75. PMID: 12369742
- Macan M, Konjevoda P, Lovrić J, Koprivanac M, Kelava M, Vrkić N, Bradamante V. The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in Wistar and fisher rats. Basic Clin Pharmacol Toxicol 2011;108:428–35. doi: 10.1111/j.1742-7843.2011. 00674.x
- Ciriolo MR, Mavelli I, Rotilio G, Borzatta V, Cristofari M, Stanzani L. Decrease of superoxide dismutase and glutathione peroxidase in liver of rats treated with hypolipidaemic drugs. FEBS Lett 1982;144:264–8. doi: 10.1016/0014-5793(82)80651-0
- Ciriolo MR, Rossi L, Mavelli I, Rotilio G, Borzatta V, Cristofori M, Barbanti M. The effects of hypolipidaemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liver. Arzneimittelforschung 1984;34:465–7. PMID: 6540105
- Abdoli N, Heidari R, Azarmi Y, Eghbal MA. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol 2013;27:287–94. doi: 10.1002/jbt.21485
- Eghbal MA, Abdoli N, Azarmi Y. Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity. Arh Hig Rada Toksikol 2014;65:101–8. doi: 10.2478/10004-1254-65-2014-2398
- Yaribeygi H, Mohammadi MT, Rezaee R, Sahebkar A. Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. J Cell Biochem 2018;119:7458–69. doi: 10.1002/jcb.27055
- Wood WG, Eckert GP, Igbavboa U, Müller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010;1199:69–76. doi: 10.1111/j.1749-6632.2009.05359.x
- Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003;23:6264–71. doi: 10.1523/JNEUROSCI.23-15-06264.2003
- Balakumar P, Varatharajan R, Nyo YH, Renushia R, Raaginey D, Oh AN, Akhtar SS, Rupeshkumar M, Sundram K, Dhanaraj SA. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014;90:36–47. doi: 10.1016/j.phrs.2014.08.008
- Fatani SH, Naderaralli EK, Panchiani S, Shah F, Wong C. The effects of dietary obesity on protein expressions of insulin signalling pathway in rat aorta. Drug Discov Ther 2008;2:256–61. PMID: 22504637
- Nezić L, Skrbić R, Dobrić S, Stojiljković MP, Jaćević V, Stoisavljević Satara S, Milovanović ZA, Stojaković N. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol 2009;104:185–91. doi: 10.1111/j.1742-7843.2008.00302.x
- Simsek Ozek N, Burak Bal I, Yildirim S, Rustu Inur, Severcan F. Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles. Biochim Biophys Acta 2014;1840:406–14. doi: 10.1016/j.bbagen.2013.09.010
- Pravilnik o zaštiti životinja koje se koriste u znanstvene svrhe [Regulation of the protection of animals used for scientific purposes, in Croatian]. Narodne novine 55/2013.
- Guillen J. FELASA guidelines and recommendations. J Am Assoc Lab Anim Sci 2012;51:311–21. PMCID: PMC3358979
- Drury JA, Nycyk JA, Cooke RW. Comparison of urinary and plasma malondialdehyde in preterm infants. Clin Chim Acta 1997;263:177–85. doi: 10.1016/s0009-8981(97)00051-x
- Ellman GL. A colorimetric method for determining low concentrations of mercaptans. Arch Biochem Biophys 1958;74:443–50. doi: 10.1016/0003-9861(58)90014-6
- Rowe P. Essential Statistics for the Pharmaceutical Sciences. Chichester: Wiley; 2007. ISBN: 9780470034682
- Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol 2002;54:143–50. PMID: 12139111
- Liang H, Feng Y, Cui R, Qiu M, Zhang J, Liu C. Simvastatin protects against acetaminophen-induced liver injury in mice. Biomed Pharmacother 2018;98:916–24. doi: 10.1016/j.biopha. 2017.12076
- Zhang F, Sun D, Chen J, Guan N, Huo X, Xi H. Simvastatin attenuates angiotensin II-induced inflammation and oxidative stress in human mesangial cells. Mol Med Rep 2015;11:1246–51. doi: 10.3892/mmr.2014-2871
- Zinellu A, Mangoni AA. A systematic review and meta-analysis of the effect of statins on glutathione peroxidase, superoxide dismutase, and catalase. Antioxidants (Basel) 2021;10(11):1841. doi: 10.3390/antiox10111841
- Verma K, Makwana S, Paliwal S, Paliwal V, Jain S, Paliwal S, Sharma S. Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidaemic rats. Curr Res Pharmacol Drug Discov 2022;3:100088. doi: 10.1016/j.crphar.2022.100088
- Wahba MGF, Messiha BAS, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol 2016;54:1705–15. doi: 10.3109/13880209. 2015.1125931
- Aberg F, Appelkvist EL. Clofibrate and di(2-ethylhexyl) phthalate increase ubiquinone contents without affecting cholesterol levels. Acta Biochim Pol 1994;41:321–9. PMID: 7856403
- Arnaiz LS, Travacio M, Monserrat AJ, Cutrín JC, Llesuy S, Boveris A. Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1997;1360:222–8. doi: 10.1016/s0925-4439(97)00004-5
- Tkác I, Molcányiová A, Javorský M, Kozárová M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res 2006;53:261–4. doi: 10.1016/j.phrs.2005.12.002
- Jiao H-L, Zhao B-L. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002;185:172–9. doi: 10.1006/taap.2002.9538
- Shore LJ, Fenselau C, King AR, Dickinson RG. Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos 1995;23:119–23. PMID: 7720514
- Sun B, Xie Y, Jiang J, Wang Y, Xu X, Zhao C, Huang F. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. Lipids Health Dis 2015;14:27. doi: 10.1186/s12944-015-0032-3